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A B S T R A C T
Current organophosphorus nerve agent medical countermeasures do not directly address the nicotinic
effects of poisoning. A series of antinicotinic bispyridinium compounds has been synthesized in our
laboratory and screened in vitro. Their actions can include open-channel block at the nicotinic receptor
which may contribute to their efficacy. The current lead compound from these studies, MB327 1,10-
(propane-1,3-diyl)bis(4-tert-butylpyridinium) as either the diiodide (I2) or dimethanesulfonate (DMS)
has been examined in vivo for efficacy against nerve agent poisoning. MB327 I2 (0–113 mg kg1) or the
oxime HI-6 DMS (0–100 mg kg 1), in combination with atropine and avizafone (each at 3 mg kg1) was
administered to guinea-pigs 1 min following soman poisoning. Treatment increased the LD50 of soman in
a dose-dependent manner. The increase was statistically significant (p < 0.01) at the 33.9 mg kg1
(MB327) or 30 mg kg1 (HI-6) dose with a comparable degree of protection obtained for both compounds.
Following administration of 10 mg kg1 (i.m.), MB327 DMS reached plasma Cmax of 22 mM at 12 min with
an elimination t1/2 of 22 min. In an adverse effect study, in the absence of nerve agent poisoning, a dose of
100 mg kg1 or higher of MB327 DMS was lethal to the guinea-pigs. A lower dose of MB327 DMS
(30 mg kg1) caused flaccid paralysis accompanied by respiratory impairment. Respiration normalised by
30 min, although the animals remained incapacitated to 4 h. MB327 or related compounds may be of
utility in treatment of nerve agent poisoning as a component of therapy with atropine, anticonvulsant
and oxime, or alternatively as an infusion under medical supervision.
Crown Copyright ã 2015 Published by Elsevier Ireland Ltd. This is an open access article under the Open
Government Licence (OGL) (http://www.nationalarchives.gov.uk/doc/open-government-licence/ver-
sion/3/)
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Medical countermeasures (MedCMs) to nerve agent poisoning
do not currently contain a component which directly counteracts
the effect of elevated acetylcholine at nicotinic synapses. While* Corresponding author.
E-mail address: meprice1@dstl.gov.uk (M.E. Price).
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0378-4274/Crown Copyright ã 2015 Published by Elsevier Ireland Ltd. This is an open acce
gov.uk/doc/open-government-licence/version/3/)oximes alleviate this by restoring acetylcholinesterase (AChE)
function at these sites (Timperley et al., 2011), there are limitations
to the efficacy of oximes for AChE inhibited by some nerve agents
such as tabun (Heilbronn and Tolagen, 1965) or where rapid
‘ageing’ of the inhibited enzyme occurs such as with the AChE-
soman adduct (Fleisher et al., 1965). A series of bispyridinium
compounds has been synthesized and screened for ion-channel
blocking properties at the nicotinic receptor (Timperley et al.,
2005). In vitro studies have demonstrated that one of thesess article under the Open Government Licence (OGL) (http://www.nationalarchives.
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guinea-pig, rat and human muscle preparations (Seeger et al.,
2012; Turner et al., 2011). Related compounds also bind to the
human alpha 7 nicotinic acetylcholine receptor and the nicotinic
receptors from electric eel Torpedo californica (Niessen et al., 2012a,
2011). MB327 binds to the human M5 muscarinic acetylcholine
receptor (Niessen et al., 2012b) and causes a relaxation of rat
jejunum smooth muscle (Königer et al., 2013).
MB327 (Fig. 1) has been assessed in vivo in mouse and guinea-
pig models of nerve agent poisoning. In atropine-pretreated mice,
MB327 (referred to as P62) provided some protection, reducing an
LD95 dose of soman to an LD50 (Schoene et al.,1976). In guinea-pigs,
MB327 DMS, in combination with physostigmine salicylate and
hyoscine hydrobromide, protected 4/8 of animals against a
5  LD50 challenge of sarin and 5/8 against 5  LD50 of tabun. In
comparison, HI-6 protected 8/8 and 1/8 animals, respectively
(Turner et al., 2011). In the same model, protection against soman
provided by MB327 DMS was 6/8, and by HI-6, 7/8 (Timperley et al.,
2012). This broadly similar efficacy across nerve agents with
different oxime sensitivities and ageing rates suggests MB327 and
related bispyridinium compounds may provide a broad-spectrum
adjunct to conventional therapy for nerve agent poisoning.
However, these previous studies did not use the additional therapy
components used in current MedCMs (antimuscarinic and
anticonvulsant) (Timperley and Tattersall, 2015). An assessment
was therefore conducted to determine if MB327 was beneficial
when administered in combination with the currently-fielded UK
MedCM combination of atropine sulfate and avizafone hydrochlo-
ride. A comparison was also made to a combination treatment
comprised of atropine sulfate, avizafone and the oxime HI-6.
Soman was selected as the challenge agent for these studies as
soman-inhibited AChE ages rapidly rendering it resistant to oxime
reactivation. Poisoning by soman thus poses one of the more
difficult challenges for MedCM.
Both MB327 I2 and MB327 DMS were studied. Initially, the former
was available in greater quantities than the latter, which is
synthesised from the diiodide by ion exchange (Timperley et al.,
2012). The decision was made to use MB327 I2 for efficacy studies,
adjusting its concentration to account for the different molecular
masses of MB327 I2 and MB327 DMS, and to save the latter for the
pharmacokinetic (PK) studies. The dimethanesulfonate salt is
preferable for PK studies due to its greaterwatersolubility. Syntheses
of comparable salts with a d6-deuterated linker and their use as
internal standards for mass spectrometric quantitation of MB327
I2 and MB327 DMS in guinea-pig plasma are also described.
2. Methods
2.1. Animals
All animal work was carried out under the terms and conditions
of a Project Licence (PPL 30/2864) granted by the UK Home
Office under the Animals (Scientific Procedures) Act, 1986. Male
HsdDhl:DH Dunkin–Hartley guinea-pigs were supplied by HarlanFig. 1. Antinicotinic bispyridinium compounds.Interfauna (Hillcrest, UK). Bodyweight on arrival was 233  9 g
(n = 76; mean  SD) for the efficacy study, 245  6.4 g (n = 30;
mean  SD) for the adverse events study and 334  31 g (n = 7;
mean  SD) for the PK study. The animals were allowed to
acclimatize for at least 4 days prior to study, and were kept in
standardised conditions to meet UK Home Office guidelines
(room temperature 21 C, humidity 50%). The lights were on from
06:00 to 18:00 h. Daily body weight and temperature recordings
were monitored throughout the experiment as a measure of
health and wellbeing.
2.2. Chemicals and drugs
Atropine sulfate was supplied by Sigma Ltd. (Dorset, UK),
avizafone by Roche Ltd. (Welwyn Garden City, UK), HI-6 by Phoenix
Chemicals Ltd. (Bromborough, UK) and soman by chemists
working in the UK Single Small Scale Facility, Dstl Porton Down
(>95% pure, diluted in isopropanol). d6-1,3-Dibromopropane and
other reagents were from Aldrich Ltd. (Dorset, UK) and were used
as received. Thin layer chromatography (TLC) was performed on
MK6F silica gel 60 Å plates (Whatman, USA) with detection by
iodine vapour. Nuclear magnetic resonance (NMR) data were
collected at 9.4 T using a Bruker Avance III spectrometer equipped
with a 5 mm BBFO + probehead.
2.3. Deuterated standards
Undeuterated MB327 I2 and MB327 DMS were prepared
according to a published procedure (Timperley et al., 2012).
Deuterated analogues were synthesized by Finkelstein reaction of
d6-1,3-dibromopropane with an excess of sodium iodide in acetone
(Fig. 2). The d6-1,3-diiodopropane (1) obtained was bis-quater-
nized by two molar equivalents of 4-tert-butylpyridine in boiling
nitromethane to give d6-MB327 I2. Treatment of this with a
suspension of silver(I) methanesulfonate in methanol provided
d6-MB327 DMS.
2.3.1. d6-1,3-Diiodopropane (1)
A solution of d6-1,3-dibromopropane (5.0 g, 24 mmol) in
acetone (15 ml) was added dropwise over 20 min to a stirred
solution of sodium iodide (15.0 g, 100 mmol) in acetone (55 ml) in a
250-ml round-bottomed flask. The addition caused precipitation of
sodium bromide. Stirring was continued for 12 h. The sodium
bromide was filtered off and rinsed thoroughly with acetone. The
solvent was removed from the filtrate to leave sludge. This was
partitioned between dichloromethane (55 ml) and water (30 ml)
and the aqueous layer extracted with dichloromethane (2  30 ml).
The organic layers were combined and dried (MgSO4), the drying
agent filtered off, and the solvent removed from the filtrate to leave
a mobile yellow liquid (8.56 g). Fractionation of this using a micro-
distillation apparatus gave the title compound as a pale orange
mobile liquid (6.38 g, 88%). Bp 61 C/1 mmHg. Analysis by gas
chromatography–mass spectrometry showed that it was 99% pure




d6-1,3-Diiodopropane (6.04 g, 20 mmol) was added dropwise to
a stirred solution of 4-tert-butylpyridine (8.10 g, 60 mmol) in
nitromethane (30 ml) in a 100-ml round-bottomed flask. The
mixture was heated for 18.25 h. TLC analysis of a sample versus the
starting materials, eluting with 1:2 hexane–acetone, was per-
formed. None of the d6-1,3-diiodopropane was seen upon
developing the plates with iodine vapour; a main spot at retention
factor (Rf) 0.05 (desired product), a fainter one at Rf 0.15
Fig. 2. Synthesis of the deuterated internal standard d6-MB327 DMS.
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excess of 4-tert-pyridine, were observed. The mixture was heated
under reflux for a further 13 h, giving a total reflux time of 31.25 h.
TLC of the mixture differed little from the previous analysis,
signifying that the reaction was essentially complete. The solvent
was removed from the mixture to yield a solid which was dried
further using a vacuum pump. The solid obtained was dissolved in
the minimum volume of hot isopropanol and left to cool slowly.
The pale orange crystals produced were filtered off and dried to
constant weight using the vacuum pump, and comprised the pure
product (9.50 g, 83%). Mp 241–242 C. 1H NMR (400 MHz, CDCl3)
d = 9.72–9.69 (4H, m, 2- and 6-H), 7.95–7.93 (4H, m, 3- and 5-H),
1.42 (18H, s, 6  CH3) ppm.
2.3.3. 1,10-(d6-Propane-1,3-diyl)bis(4-tert-butylpyridinium)
dimethanesulfonate (d6-MB327 DMS)
The previous compound (4.58 g, 8.0 mmol) and methanol
(100 ml) and a magnetic stirrer bead were added to a 500-ml two-
necked round-bottomed flask equipped with a dropping funnel
and condenser topped by a guard tube (containing anhydrous
calcium chloride). The stirred mixture was heated to an external
temperature of 60 C using an oil bath until full dissolution of the
d6-MB327 I2 occurred. A few drops of methanesulfonic acid were
added to the resulting solution to adjust the pH to 4. A solution of
silver(I) methanesulfonate (3.31 g, 16.3 mmol) in acetonitrile
(35 ml) was added dropwise with stirring at 60 C over 25 min. A
sticky and stringy precipitate formed on addition. By the end of the
addition this had been replaced by a yellow granular precipitate.
Stirring at 60 C was continued for a further 90 min. The mixture
was allowed to cool to room temperature and stirred at ambient
temperature for 12 h. The precipitate of silver(I) iodide was filtered
off and rinsed thoroughly with methanol. The solvent was
removed from the filtrate and the crude product – a viscous
pale-brown liquid – was dried using a vacuum pump. This crude
product (4.54 g) was dissolved in the minimum volume of
isopropanol (8 ml), allowed to cool, anhydrous diethyl ether
added until the mixture started to become turbid, and swirled
while cooling in an acetone–cardice bath at 78 C. Crystals
formed slowly. The mixture was left overnight at ambient
temperature. The white crystals obtained were filtered off, rinsed
with anhydrous diethyl ether, and dried to constant weight at
130 C using a vacuum pump. Analytically pure product was
isolated as a white solid (2.50 g, 62%). Mp 180–185 C. 1H NMR
(400 MHz, CDCl3) d = 9.67 (4H, d, J = 6.9 Hz, 2- and 6-H), 7.86
(4H, d, J = 6.9 Hz, 3- and 5-H), 2.92 (6H, s, SCH3), 1.36 (18H, s,
6  CH3) ppm.
2.4. Pharmacokinetics
2.4.1. Surgery
Under general anaesthesia (isoflurane) guinea-pigs were
implanted with carotid cannulae (25 cm round-tip polyurethane,
2 Fr gauge (Instech-Solomon, USA)) which were exteriorisedbetween the scapulae. The animals were connected using a harness
and tether (Covance harness, Instech Solomon, USA) to a syringe
and pump (CMA402, CMA microdialysis, Sweden) delivering
heparinised saline (5 IU ml1, 0.5 ml min1) to maintain patency.
The syringes and solution were changed daily. The animals were
allowed to recover for 48 h prior to MB327 DMS administration.
2.4.2. Automated blood sampling
A total of 15 samples, each of 250 ml, were collected following
administration of MB327 DMS (10 mg kg1, i.m.) using an
automated blood sampling system (ABS; Instech Solomon, USA).
Sampling time-points were: 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120,
150, 180, 210 and 240 min. These were selected based on previous
data obtained with the structurally similar compound HI-6
(Mumford et al., 2013).
2.4.3. Sample preparation
Following collection, blood samples were removed from the
refrigerated ABS carousel and centrifuged for 1 min (13,300 rev-
olutions min1R17,000  g, in a Heraeus Pico 17 centrifuge,
Thermo Fisher Scientific, UK); the plasma was then decanted from
the red cell fraction into a separate vial. The samples were
immediately frozen and then stored at 80 C.
2.4.4. MB327 quantitation in plasma
Plasma samples (10 ml) were transferred to new Eppendorf
tubes (Hamburg, Germany) and proteins precipitated by adding
acetonitrile (200 ml containing 0.5 mg ml1 of d6-MB327 DMS). The
contents of the tubes were vortex mixed for 30 s, then centrifuged
for 5 min at 12,000 revolutions min1R10,000  g. In each case,
supernatant (150 ml) was transferred to a glass vial and evaporated
to dryness under nitrogen using a TurboVap1 LV automated
evaporation system (Biotage; Uppsala, Sweden). Samples were
reconstituted with 150 ml of acetonitrile–water (1:1 v/v containing
0.1% by volume of formic acid; Aldrich Ltd., Dorset, UK) and
transferred to high recovery liquid chromatography (LC) vials for
analysis using a Thermo Fisher Scientific Quantum TSQ1 mass
spectrometer (Thermo Fisher Scientific Oxoid Ltd., Hampshire, UK)
equipped with a Thermo-Finnigan Surveyor HPLC pump and
autosampler (Thermo-Finnigan; Hemel Hempstead, UK). An
Obelisc R reverse-phase analytical LC column (SIELC Technologies;
Wheeling, IL USA) of dimensions 150 mm  2.1 mm  5 mm was
used and a guard column was fitted to the column inlet.
The mobile phases were A (40 mM ammonium formate, pH 3)
and B (acetonitrile), and the chromatography eluent comprised
50% A and 50% B. The run time was 6 min and the flow rate was
0.5 ml min1. An injection volume of 5 ml was used. Concentrations
of MB327 DMS ranging from 100 to 10,000 ng ml1 in guinea-pig
plasma (K2 EDTA, Harlan Laboratories UK Ltd., Oxfordshire) were
used for calibration. The mass spectrometer was operated in
electrospray ionisation (ESI) positive ion mode. A selected reaction
monitoring method was created to monitor two transitions for the
MB327 DMS analyte (m/z 156–105 and m/z 156–119) and
M.E. Price et al. / Toxicology Letters 244 (2016) 154–160 157deuterated internal standard (m/z 159–108 and m/z 159–122). The
scan time was 0.2 s per transition. The ESI voltage was set to
3500 V, sheath gas pressure to 50 l min1, auxiliary gas to
10 l min1, capillary temperature to 225 C, capillary offset to 10,
and the tube lens offset to 120 V.
For quantification, MB327 DMS peak area ratios were calculated
using the internal standard and compared to those calculated from
the calibration standards (Fig. 3). Data were processed using the
Quant browser within the Thermo XcaliburTM Software (Thermo
Fisher Scientific Oxoid Ltd., Hampshire, UK).
2.5. Adverse effects
Some animals were dosed with MB327 DMS in the absence of
nerve agent challenge to determine whether it produced adverse
effects in unpoisoned animals. Following the initial assessment of
adverse effects, MB327 (30 mg kg1) was administered in combi-
nation with atropine (3 mg kg1) and avizafone (3 mg kg1), in the
absence of nerve agent. In these studies, signs of poisoning
were observed closely for up to 2 h, with periodic checks to 4 h,
at which point the surviving animals were culled by overdose
of anaesthetic.
2.6. Efficacy study
The purpose of the experiment was to determine the 24-h LD50
of soman in the presence of MB327 I2 or HI-6 DMS in combination
with atropine and avizafone in the guinea-pig. The LD50 of soman
in combination with atropine, avizafone and HI-6 was determined
using the Dixon staircase method (Dixon, 1965). The LD50 values
for atropine, avizafone and MB327 were derived using an
adaptive probit method (Rice et al., 2015). Initially, the 24-h
outcome determined the next challenge dose. Where an animal
survived, the next dose in the curve was higher by one dose step,
where an animal died the next dose in the curve was lower by one
dose step. The dose step was fixed at 0.1 Log10 unit. Each
determination was carried out in triplicate and an interim
analysis was conducted at n = 4 per group. The remaining six
animals in each determination were dosed at the predicted LD20,
LD50 and LD80 to provide a final dose-response relationship


















































Fig. 3. Extracted ion chromatograms showing MB327 DMS in a sample of guinea-pig pla
concentration of d6-MB327 DMS internal standard (bottom left), and the internal calibrat
in control plasma. (RT = retention time, MA = mass area, of peak).2.6.1. Nerve agent and therapy administration
Soman was diluted in physiological saline (0.9% w/v) to the
required concentration and administered subcutaneously between
the scapulae at 1 ml kg1. Atropine (3 mg kg1) and avizafone
(3 mg kg1) plus MB327 or HI-6 was administered 1 min following
poisoning, intramuscularly in the thigh. The animals were
observed periodically up to 6 h post-poisoning and again at 24 h
post-poisoning, at which time surviving animals were culled by
cervical dislocation.
A post-mortem examination of all soman-treated animals was
carried out, with emphasis on the thoracic and abdominal organs.
The examination looked for pulmonary haemorrhage and hyper-
inflation, and for intussusception in the gastrointestinal tract
(Wetherell et al., 2007).
2.6.2. LD50 estimation and statistical analysis
This experiment used an adaptive model for generation of dose
lethality data (Russell et al., 2009; Stallard, 2006). A probit
regression model was used to fit a dose response curve to the
survival data using the bias-reduced generalized linear model
(brglm) method in the R statistical software package (R Core Team,
2014). The LD50 was calculated from the probit regression by
rearranging the model formula in terms of dose (Russell et al.,
2009; Stallard, 2006). Approximate standard errors for the fit to
this dose estimate were calculated using the transformation
method and confidence intervals using the delta method. At the
conclusion of the study, all LD50 values were reanalysed to test for a
dose-effect across the three treatment groups (Firth, 1993;
Kosmidis, 2010). Comparisons of LD50 were made against the
base of the model (atropine 3 mg kg1, avizafone 3 mg kg1 and
MB327 0 mg kg1 group for MB327 and the LD50 in the absence of
therapy for HI-6) to show differences between groups. A
predetermined alpha level of 0.05 was taken to indicate a
statistically significant difference in all cases.
3. Results
3.1. Pharmacokinetics
Following intramuscular administration of 10 mg kg1 MB327




















sma taken for PK analysis (top left) versus guinea-pig plasma spiked with a known
ion standards for MB327 DMS (top right) and its deuterated analogue (bottom right)
Fig. 4. Time-profile of concentration of MB327 DMS in guinea-pig plasma following
its i.m. administration at 10 mg kg1. Data are shown as mean  SEM (n = 7).
Fig. 5. 24-h LD50 for subcutaneous soman in the guinea-pig following treatment
with atropine (3 mg kg1), avizafone (3 mg kg1) and the indicated dose of either
MB327 I2 (blue open circles and dashed line) or HI-6 DMS (red closed squares).
*p < 0.05 vs. LD50 in the absence of therapy (HI-6) or, vs. atropine and avizafone
therapy. The 0 mg kg1 dose for each treatment indicates atropine + avizafone.
Dashed line indicates the LD50 for soman in the absence of therapy. Data are shown
as mean  SE.
158 M.E. Price et al. / Toxicology Letters 244 (2016) 154–160concentration profile is shown (Fig. 4). MB327 was eliminated with
a half-life of 22 min.
3.2. Adverse effects
Any dose of MB327 DMS higher than 30 mg kg1 caused acute
respiratory failure leading to death within 30 min (Table 1). At
30 mg kg1 respiration was impaired and mild flaccid paralysis
evident. These animals recovered within 1 h. At a dose of
10 mg kg1, no adverse effects were observed. There was no
difference in observed signs of poisoning in the group receiving
atropine, avizafone and 30 mg kg1 MB327 when compared to the
group receiving 30 mg kg1 MB327 alone.
3.3. Efficacy against soman poisoning
Both HI-6 and MB327 I2 in combination with atropine and
avizafone protected guinea pigs against the effects of soman. An
increase in 24-h LD50 for subcutaneous soman with increasing
MB327 or HI-6 dose was observed, this peaked at 30 mg kg1 for
both compounds. A further increase in dose (to 100 mg kg1)
provided no further increase in protection. The increase in LD50
was statistically significant compared to the atropine/avizafone
treatment group (p < 0.01) for MB327 at 33.9 mg kg1. In the HI-6-
treated groups, the LD50 was significantly increased compared to
the soman group 30 and 100 mg kg1 doses (Fig. 5). Intussuscep-
tion occurred in a few animals (n = 11), but there was no correlation
with either agent or therapy dose (n = 3 at 0 mg kg1; n = 2 at 11.3
and 33.8 mg kg1; n = 4 at 113 mg kg1).
The distribution of times to death after lethal doses of soman, in
each therapy dose group, probably reflects the adverse effects of
MB327 (Table 2). The optimal therapy dose (33.8 mg kg1)
prevented death for at least 6 h in all animals. However, at the
higher dose (113 mg kg1) deaths occurred earlier, in the 0–1 h
period. As this dose was toxic in the absence of nerve agent, theTable 1
Survival time of guinea-pigs administered MB327 DMS. Guinea pigs were
administered the indicated dose of MB327 alone or in combination with atropine
sulfate (3 mg kg1) and avizafone (3 mg kg1) (30+). n.a. - surviving animals were all
in good condition at the end of the observation period (4 h).
MB327 DMS dose (mg kg1) Mean time to death  SD (min) n
500 5.3  0.7 4
250 12.6  8.1 4
100 17.1  4.0 4
30 n.a. 6
30+ n.a. 6
10 n.a. 6early deaths cannot necessarily be attributed to nerve agent
poisoning.
4. Discussion
When given intramuscularly in combination with atropine and
avizafone, both MB327 I2 and the oxime HI-6 DMS provided similar
protection following acute (subcutaneous) soman poisoning. In
both cases, the protection ratio (LD50 with treatment/LD50 without
treatment) achieved by the optimal dose of each compound was
approximately 2.8.
Although there is some non-competitive antinicotinic effect
attributable to HI-6 (Tattersall, 1993), it is less potent and effective
than MB327 in terms of providing direct functional recovery in
soman-poisoned neuromuscular preparations in vitro (Seeger
et al., 2011; Tattersall, 1993; Turner et al., 2011), and therefore,
given its rapid administration following poisoning it is likely that
the protective effect of HI-6 is attributable to reactivation of
unaged AChE in the guinea pig. MB327 I2 lacks an oxime group and
thus its mechanism of action cannot involve reactivation of
inhibited AChE (Schoene et al., 1976). Given that beneficial
antinicotinic effects are exhibited by MB327 in vitro it follows
that this action may be responsible for the protection seen in vivo.
Such action is desirable because, by acting downstream of AChE
inhibition, it should provide broad spectrum protection against any
nerve agent (Timperley et al., 2012; Turner et al., 2011) and may
still be effective following a delay in its administration, whereas
ageing of some agent-AChE complexes would provide resistance
to an oxime-based therapy following such a delay.
Male animals were used in this study to control for the potential
effects of gender and hormonal changes on variability of response.
A comparison of the toxicity of three nerve agents in male and
female guinea pigs (Fawcett et al., 2009) demonstrated no
difference in toxicity of soman in male and female guinea pigs,
although there was variation in toxicity of sarin and VX with
gender and age. Where efficacy studies of HI-6 directly comparing
male and female animals have been carried out there were no
differences in guinea pigs, although there were marked differences
between male and female rats (Lundy et al., 1989).
Although not used in this study, pretreatment with pyridos-
tigmine bromide is part of the UK provision of medical counter-
measures to nerve agents (Timperley and Tattersall, 2015). As a
combination of antimuscarinic (hyoscine), MB327 and carbamate
Table 2
Percentage of animals dying at <1 h, 1–6 h, 6–24 h or alive at 24 h following soman (at all doses used, dose range shown in final column) and therapy comprising atropine
(3 mg kg1), avizafone (3 mg kg1) and the indicated dose of MB327 I2.
MB327
(mg kg1)
%Dead <1 h %Dead 1–6 h %Dead 6–24 h %Alive 24 h Agent dose range (mg kg1)
0 (n = 15) 26.7 6.7 33.3 33.3 22.8–57.5
11.3 (n = 21) 23.8 4.8 33.3 38.1 25.8–182
33.8 (n = 18) 0 0 66.7 33.3 51.1–232
113 (n = 18) 38.9 11.1 27.8 22.2 45.7–232
M.E. Price et al. / Toxicology Letters 244 (2016) 154–160 159(physostigmine) was effective as a therapy in guinea-pigs post-
poisoning with soman (Timperley et al., 2012; Turner et al., 2011),
there is no reason to believe that MB327 therapy would be
incompatible with a carbamate pretreatment.
MB327 and related bispyridinium compounds have been shown
to affect a number of other targets that could conceivably provide
protection following nerve agent poisoning including mAChRs
(Niessen et al., 2012b), nAChR orthosteric sites (Niessen et al.,
2013) and AChE (Niessen et al., 2013, 2011). Antagonism at mAChRs
classically provides the mainstay of protection against nerve agent
poisoning and MB327 shows a similar or greater affinity for
inhibition of mAChRs than for its channel block observed at nAChR
(Königer et al., 2013; Mawdsley and Green, 2015; Niessen et al.,
2012b). In previous studies and those reported here, relatively high
doses of antimuscarinic (hyoscine or atropine) were used and it is
unclear if MB327 would provide additional effective muscarinic
inhibition over and above that provided by these antimuscarinics.
It has recently been suggested that the atropine concentrations
achieved clinically in patients being treated for OP poisoning may
not fully block all muscarinic actions, at least in the isolated ileum
preparation used, and that a degree of additional muscarinic block
provided by MB327 could be achieved (Königer et al., 2013).
Careful characterisation of both the PK and PD of both the
antimuscarinic and MB327 in the animal model of nerve agent
poisoning is likely to be required to clarify which mechanism is
responsible for the protection. Additionally, the identification of
compounds with actions similar to MB327 at nAChRs, but which
exhibit better nicotinic selectivity, could also provide further
clarification of this mechanism. MB327 has no effect on the
inhibition of AChE by soman (Schoene et al., 1976) and, whilst the
early administration of a high potency carbamate (physostigmine)
AChE inhibitor has been shown to be beneficial following nerve
agent poisoning (Wetherell et al., 2006, 2007), it is unlikely that
MB327 administration post-exposure would have a protective
effect given its very low potency at this target (IC50 600 mM)
(Niessen et al., 2013).
A major finding in this study has been the observation of severe
adverse effects at doses of MB327 very similar to those that provide
protection. Animals administered MB327 DMS alone exhibited a
flaccid paralysis and respiratory difficulties which were rapidly
fatal at the highest doses tested. These signs of poisoning are
consistent with an antinicotinic neuromuscular block possibly due
to interactions at the ion channel, the orthosteric ACh binding sites
or at both. There does appear to be some mutual antagonism
between AChE inhibition by soman and the adverse effects of
MB327 as demonstrated by the survival in soman-poisoned
animals treated with the highest dose of MB327. In the absence
of soman poisoning a very robust and rapid lethality of MB327 DMS
was observed in all animals. A similar effect is seen with atropine.
The atropine dose (2 mg) in the L4A1ComboPen1 autoinjector
issued to UK forces for self-/buddy-aid is deemed to be the
maximum intramuscular dose compatible with military activities
(Cullumbine et al., 1952). This is due to the adverse effects of
atropine in the absence of nerve agent, where doses as low as 5 mg
may cause a sensation of dizziness, giddiness or light-headedness(Cullumbine et al., 1955; McKee et al., 1952) and doses of 10 mg
may cause delirium (Ostfeld et al., 1959, 1960). These doses are,
however, lower than those which could be employed in a clinical
setting, where doses of up to 200 mg intravenously over 10–15 min
have been used to treat nerve agent intoxication (Foroutan, 1997;
Newmark, 2004).
No attempt has been made in these studies to optimise aspects
of the MB327 administration regimen other than dose. The
pharmacokinetics for MB327 are presented here for the first time
and are similar to those of related oximes (Mumford et al., 2013)
with clearance from the circulation being rapid. This is not ideal for
protection via an antinicotinic action, as the continued presence of
the drug is required for it to exert its beneficial actions via channel
block (Tattersall, 1993; Turner et al., 2011). In addition, the
relatively high Cmax resulting from the bolus administration may
be responsible for the adverse effects via excessive nicotinic
receptor antagonism.
The adverse effects observed in this study may make it difficult
to use this particular compound as a therapy against nerve agent
poisoning. However, careful infusion and titration to effect could
be used to achieve a better pharmacokinetic profile more suited to
the hypothesised mechanism of action whilst avoiding adverse
effects. Such an approach may be better aimed at casualty
management in medical care facilities, where sustained adminis-
tration by (for example) intravenous or intraosseous infusion or a
suitably formulated sustained release drug preparation could be
used. Animal studies should be carried out in order to determine
the efficacy of such an approach. Additionally, efforts to improve
the understanding of the structural and chemical characteristics
defining nicotinic channel interactions may lead to development of
compounds with increased efficacy and improved safety profiles.
5. Conclusions
A non-competitive nicotinic ion channel blocker (MB327), in
combination with an antimuscarinic (atropine) and an anticonvul-
sant (avizafone), protected guinea-pigs against soman toxicity
with an efficacy equivalent to that of the oxime HI-6. It is
hypothesised that the antinicotinic action of MB327 is responsible
for the protection observed, although interactions at other targets
involved in cholinergic signalling may contribute. MB327 was not
without adverse effects, these were severe and probably resulted
from block of neuromuscular transmission of the respiratory
muscles. MB327 was rapidly cleared from the circulation
potentially limiting its protective effect. These data suggest that
PK and adverse effect profiles of any additional candidate
compounds should be conducted alongside further efficacy studies
in the assessment of these compounds as promising broad-
spectrum nerve agent antidotes.
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